We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Guidance Seeks to Speed Reviews of Biosimilars for Fewer Conditions of Use
FDA Guidance Seeks to Speed Reviews of Biosimilars for Fewer Conditions of Use
As part of its ongoing efforts to encourage biosimilars, the FDA issued draft guidance yesterday on the agency’s abbreviated review pathway for sponsors of biosimilars with more limited conditions of use than the reference product.